Biography
Dr Puttick completed a PhD in Chemistry at the University of Nottingham in 2012 where his study was focussed on the use of nuclear magnetic resonance spectroscopy to understand the spatial organisation of ionic liquids. Following his PhD, he moved to the University of Cambridge as a Research Fellow focussed on the discovery of magnetic resonance imaging biomarkers of neurodegeneration in Huntingtons Disease.
He moved to Australia in 2013 to take up a position as a Research Fellow at the University of Queensland focussed on the development of theranostics for primary brain cancers. In this position he developed a keen interest in the field of nuclear medicine and has developed a portfolio of active research in this field.
Dr Puttick moved to CSIRO in 2018 to drive a program of research in theranostic development. He now manages a $12.5M research portfolio leading 24 scientists across 7 projects focussed on; discovery of diagnostic biomarkers; discovery and engineering of biological ligands; design and development of diagnostic devices; clinical evaluation of biologic therapeutics and production of medical radioisotopes.
To date, Dr Puttick has published 42 journal articles, 1 book chapter and filed 1 patent and his research has attracted ~$10.5M in research grant funding and industry investment.
Other Interests
Dr Puttick is a keen woodworker and woodturner
Professional Areas
Current Roles
-
Project Leader
Theranostic Discovery Program -
Project Leader
UQ/CSIRO Centre for Personalised Nanodiagnostics -
Project Leader
Development and Translation of PoC COVID-19 Diagnostics -
Project Leader
Development of Targeted Alpha Therapy for Australia -
Project Leader
Clinical Translation of Antibody Theranostics for Ovarian Cancer
Academic Qualifications
-
2008
MSci Chemistry
The University of Nottingham -
2012
PhD
The University of Nottingham
Professional Experiences
-
2011-2012
Research Fellow
The University of Cambridge -
2013-2018
Research Fellow
The University of Queensland
Grants
-
2014-2014
The University of Queensland Early Career Researcher Grant - "Imaging Hypoxia in Glioblastoma Multiforme" - $20,500
-
2015-2017
Cure Brain Cancer Foundation Innovation Grant - " Developing novel, EphA2 targeted PET molecular imaging technology for glioma" - $219,711
-
2017-2020
CSIRO R+ - "Increasing Therapeutic Delivery to Brain Tumours through In Vivo Click Chemistry" - $315,000
-
2018-2018
Avners Pancreatic Foundation Grant - "A Novel Theranostic for Pancreatic Cancer" - $100,000
-
2019-2021
CSIRO R+ - "Reducing the Impact of Brain Trauma through Prevention of Glial Scar Formation" - $315,000
-
2019-2021
CSIRO R+ - "Theranostics and Diagnostics for Precision Oncology" - $315,000
-
2019-2021
NHMRC Project - "Nanomedicine Strategies for Early Detection and Treatment of Brain Metastases" - $667,521
-
2020-2020
Avners Pancreatic Cancer Foundation - "Development of a Theranostic for Pancreatic Cancer" - $100,000
-
2020-2021
Mark Hughes Foundation - "The Development and Clinical Translation of Blood-Based Diagnostics for Brain Cancer" - $195,250
-
2020-2022
CSIRO R+ - "Developing a Microfluidics Platform for Dose-on-Demand Peptide Receptor Radionuclide Therapy (PRRT)" - $336,000
-
2020-2024
MRFF Emerging Priorities - "A New Targeted Radio-Imaging Agent to Guide Targeted Therapy for Epithelial Ovarian Cancer" - $1,893,306
-
2020-2020
Innovation Connections - "Development of NanoYeast for Diagnostic Devices" - $98,518
-
2020-2020
US NIH Rapid Acceleration of Diagnostics - "Point-of-Care Antigen Testing for COVID-19" - $1,410,000